In Brief: McNeil Ultram
Executive Summary
McNeil Ultram: FDA Drug Abuse Advisory Committee meeting scheduled for Feb. 19 has been postponed until April, so that the committee has sufficient time to review a large amount of data from multiple sources, the agency said. The committee will discuss a scheduling action for tramadol and evaluate the effectiveness of the independent steering committee in detecting and preventing Ultram abuse. Ultram has been available since March 1995. In March 1996, the company sent a "Dear Doctor" letter noting 115 cases of drug abuse, withrawal or overdose and 83 cases of seizures during the first year of use...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth